Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab

Beer Institute Poll: 68% of Americans Support Extending Tax Relief for All Brewers and Beer Importers Washington, DC, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Today, the Beer Institute released the results of its latest nationwide poll, finding 68 percent of American voters want Congress to continue...